Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

Eric Jonasch, MD
Published: Saturday, Feb 18, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.

Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.

Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x